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Acute promyelocytic leukemias (APLs) are characterized by the
expression of the PML-RARA oncogene, which is a product of the
15;17 chromosomal translocation. Two lines of evidence suggest
that this genetic alteration is involved in the initiation of
promyelocytic leukemogenesis in vivo: i) the t(15;17) often
represents the only cytogenetic abnormality in an otherwise-
normal karyotype; ii) PML-RARA is able to initiate leukemogenesis
in mouse models on expression in hematopoietic stem cells
(HSCs) or progenitors, giving rise to a disease that recapitulates
clinical and morphological features of human APLs.1 APL onset in
mice, however, occurs after a long latency and with a low
penetrance, suggesting that, like other cancers, APL is a multistep
disease, whereby PML-RARA cooperates with secondary mutations
for the full development of the leukemia phenotype. Notably, in
the pre-leukemic phase of the disease, PML-RARA expression
induces DNA damage in HSCs/progenitors and activates DNA
repair, thus imparting a mutator phenotype that might contribute
to disease progression.2,3
Next-generation sequencing represents a powerful tool for the
discovery of genetic alterations at high resolution. To identify
gene mutations that might cooperate with PML-RARA in the
leukemogenic process, we performed whole-exome sequencing
of 5 leukemias that developed in PML-RARA transgenic mice
(mouse APLs; mAPLs) and 11 patients’ leukemias expressing
PML-RARA (human APLs; hAPLs) (Supplementary Table 1). For the
scope of this investigation, we only considered non-synonymous
single-nucleotide variants (SNVs) and small insertions/deletions
(indels) occurring in the tumor DNA with an allelic frequency
X25% (corresponding to a 450% frequency of cells carrying the
mutation in the tumor sample, assuming the majority of
mutations to be heterozygous). These experimental conditions
allow identiﬁcation of SNVs with a validation rate of 100%, as
shown by an independent sequencing approach (Sanger sequen-
cing; unpublished). We identiﬁed a total of 18 mutations in the
5 mAPLs (16 SNVs and 2 indels) and 73 mutations in the 11 hAPLs
(59 SNVs and 14 indels) (Table 1 and Supplementary Table 2). We
validated all the 16 mAPL SNVs by Sanger sequencing (the 2 indels
were not ampliﬁable for technical reasons), 18/18 randomly
selected human SNVs and 1/1 indel (Supplementary Table 2).
We next combined the results of our sequencing analyses with
those previously published for APLs (1 mAPL and 24 hAPLs),4–7
obtaining a data set of 41 APL samples (6 mAPLs and 35 hAPLs).
Analysis of this data set showed a total of 270 mutations affecting
248 human genes (231 SNVs, 34 indels and 5 splice junction
mutations—SJMs), with a low frequency of mutations per case
(B7.1 in hAPLs and B3.5 in mAPLs). In three cases (two mAPLs
and one hAPL), we found no SNVs or indels with a frequency
higher than 25%. Surprisingly, two hAPL samples showed several
hundreds of low-frequency mutations, whose signiﬁcance remains
unclear (not shown).
Of the 248 mutated genes, 9 were found in X2 patients
(recurrent mutations), and 8 showed a signiﬁcantly higher
mutation rate (qo0.005; FLT3; WT1; KRAS; CALR; CSMD1; DDR2;
REV3L and TCERG1L; Table 2 and Supplementary Table 3). FLT3 and
KRAS have been already described as cooperators of PML-RARA in
mouse models of APLs,8 whereas WT1 is infrequently mutated
in hAPLs.9 Of the remaining ﬁve, the DDR2 (discoidin domain
receptor 2) tyrosine kinase is mutated in a small subset of
squamous cell lung cancer. Notably, DDR2 mutations are critical
oncogenic events for these tumors and confer high sensitivity to
the multi-targeted kinase inhibitor dasatinib.10 We found a total of
25 mutations affecting these eight genes (APL driver mutations),
with FLT3 and WT1 being the most frequently involved (Table 2).
We next investigated the APL speciﬁcity of the identiﬁed
mutations, as compared with other subgroups of acute myeloid
leukemias (AMLs). First, we generated a data set of mutations
in all the available AML samples (n¼ 206; 196 previously
published samples7,11–14 and 10 new samples from this study
(Supplementary Tables 1 and 2)) and divided the AML samples in
different genetic/cytogenetic subgroups: i) samples with muta-
tions of nucleophosmin (NPM1þ : 58 cases); ii) normal karyotype
without NPM1 mutations (NK-NPM1 : 58 cases); iii) complex
karyotype (n¼ 22); iv) translocations or inversions affecting
CBFB/MYH11 (n¼ 11); v) t(8;21) RUNX1/RUNX1T1 (n¼ 7); vi)
trisomy 8 (n¼ 8); vii) MLL-X translocations (n¼ 10). Twenty-seven
cases did not fall into any of these categories (‘Other’).
As for PML-RARA, indirect evidence from mouse models
suggests that mutated NPM115 and fusion proteins of CBFB,
RUNX1 and MLL are initiating mutations for AMLs (reviewed in
McCormack et al.8).
AML mutations were separately analyzed in each of the
AML subgroups. We found a total of 1360 mutated genes
(B9 mutations per case), of which 153 were recurrently mutated
(X2 patients in the same subgroup) and 40 showed a
signiﬁcantly higher mutation rate (qo0.005; Table 2 and
Supplementary Table 3). Notably, included in the 40 genes
were 21 of the 22 signiﬁcantly mutated genes identiﬁed in a
recent analysis of 200 AMLs (also part of our data set7), and
additional mutated genes critical for AMLs (BCOR, ASXL1,
GATA2, SUZ12 and DDX41) or for selected epithelial cancers
(CTCF, PLCE1 and CHD4). The most frequently mutated genes
were also signiﬁcantly associated with speciﬁc AML subgroups:
FLT3, IDH1, DNMT3A and PTPN11 with NPM1þ AMLs; RUNX1,
CEBPA and GATA2 with NK-NPM1 AMLs; TP53 with AMLs with
complex karyotypes; KIT with CBFB/MYH11 AMLs; IDH1 with
AMLs with trisomy 8 (Table 2). Moreover, mutations in SF3B1,
PTPN11, DNAH9, are present in both human and mouse
leukemias.
We then analyzed the distribution of the signiﬁcantly mutated
APL and AML genes (n¼ 44) across all samples (n¼ 239). Twenty-
eight genes (B64%) were mutated in more than one cytogenetic
subgroup, covering 383 of the 416 mutations identiﬁed in all
samples (B92%). In the remaining 16 genes (B36%), mutations
were instead associated with a speciﬁc subgroup, corresponding
to just 33 of the identiﬁed mutations (B8%) and suggesting that
subgroup speciﬁcity might be due to their low frequency. Indeed,
we found a signiﬁcant correlation between frequency of muta-
tions per gene and numbers of subgroups where it is mutated
(Spearman’s coefﬁcient value of 0.93). As regards APLs, 5 of the 8
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signiﬁcantly mutated genes were also found in other AML
cytogenetic subgroups (FLT3; WT1; KRAS; CSMD1 and DDR2),
covering a total of 100 mutations, while 3 (CALR; REV3L and
TCERG1L) were only found in APLs, covering 6 mutations.
Three genes that were found signiﬁcantly mutated in other
AML subgroups were also mutated in APLs (PHF6, FAM5C and
PTPN11).
Together, these results imply that different myeloid leukemias,
including APLs, share the same subset of cooperating mutations,
and are consistent with a scenario whereby speciﬁc initiating
mutations interact with a common pool of highly heterogeneous,
yet phenotypically equivalent, cooperating mutations. Indirect
evidence, however, suggests that the pool of cooperating
mutations in AMLs is not yet entirely deﬁned, and that sequencing
of additional AMLs is needed. In fact, due to the limited size of
some samples (for example, in selected AML subgroups such as
those with rearrangements of CBFB, RUNX1 or MLL), it is likely that
our statistical analyses do not allow the identiﬁcation of all the
driver mutations in AML. Among all the mutated genes (n¼ 1559),
B3% (n¼ 45) were mutated at statistically signiﬁcant frequency
(driver mutations). Among the others (passenger mutations),
however, we identiﬁed mutations that have been causally
implicated in the pathogenesis of AMLs (for example, ETV6,
JAK2, NOTCH1, NUMA1, PRDM16, CBL, CBFB, CHIC2, ELF4, NSD1 and
PDGFRB) or other cancers (for example, PTEN, MYC, ARID1A, SF3B1,
EGFR, NF1, THRAP3, MED12, KDR, IKZF1, DAXX and SETD2).
Table 1. Mutations identified by next-generation sequencing in APLs
Cases Mutations Study
nsSNVs Indels SJMs Total
Mouse APLs
mAPL#Mi1 0 0 0 0 Present
mAPL#Mi2 1 0 0 1 Present
mAPL#Mi3 9 1 0 10 Present
mAPL#Mi4 6 1 0 7 Present
mAPL#Mi5 0 0 0 0 Present
mAPL 3 0 0 3 Wartman et al.4
Total mutations (per Pt.) 19 (3.16) 2 (0.33) 0 21 (3.50) 6 cases total
Human APLs
hAPL#Mi1 5 0 0 5 Present
hAPL#Mi2 13 3 0 16 Present
hAPL#Mi3 2 1 0 3 Present
hAPL#Mi4 3 3 0 6 Present
hAPL#Mi5 0 0 0 0 Present
hAPL#Mi6 5 1 0 6 Present
hAPL#Mi7 12 2 0 14 Present
hAPL#Mi8 1 1 0 2 Present
hAPL#Mi9 4 1 0 5 Present
hAPL#Mi10 7 1 0 8 Present
hAPL#Mi11 7 1 0 8 Present
hAPL#1 5 2 0 7 Greif et al.5
hAPL#2 3 0 0 3 Greif et al.5
hAPL#3 4 0 0 4 Greif et al.5
hAPL 12 0 0 12 Welch et al.6
TCGA-AB-2803 12 1 0 13 TCGA7
TCGA-AB-2804 7 1 0 8 TCGA7
TCGA-AB-2823 0 1 0 1 TCGA7
TCGA-AB-2840 0 1 0 1 TCGA7
TCGA-AB-2841 4 0 0 4 TCGA7
TCGA-AB-2862 7 0 0 7 TCGA7
TCGA-AB-2872 9 1 0 10 TCGA7
TCGA-AB-2897 5 0 1 6 TCGA7
TCGA-AB-2905 15 2 0 17 TCGA7
TCGA-AB-2906 9 1 0 10 TCGA7
TCGA-AB-2980 3 1 0 4 TCGA7
TCGA-AB-2982 1 1 0 2 TCGA7
TCGA-AB-2991 10 0 0 10 TCGA7
TCGA-AB-2994 6 1 0 7 TCGA7
TCGA-AB-2997 9 1 0 10 TCGA7
TCGA-AB-2998 4 1 0 5 TCGA7
TCGA-AB-2999 9 0 0 9 TCGA7
TCGA-AB-3001 8 0 2 10 TCGA7
TCGA-AB-3007 5 1 1 7 TCGA7
TCGA-AB-3012 6 2 1 9 TCGA7
Total in hAPLs (per Pt.) 212 (6.06) 32 (0.91) 5 (0.14) 249 (7.11) 35 cases
Total hþmAPLs (per Pt.) 231 (5.63) 34 (0.83) 5 (0.12) 270 (6.59) 41 cases
Abbreviations: APL, acute promyelocytic leukemia; h, human; indels, small insertion/deletions; m, mouse; nsSNV, non-synonymous single nucleotide variant;
per Pt., per patient; SJM, splice junction mutation; TCGA, The Cancer Genome Atlas.
Letter to the Editor
2
Blood Cancer Journal & 2013 Macmillan Publishers Limited
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
LR was supported by a Reintegration AIRC/Marie Curie International Fellowship in
Cancer Research. This work was supported by grants from Fondazione Cariplo to LR;
Associazione Italiana Ricerca sul Cancro (AIRC) and Italian Ministry of Health to PGP;
European Commission (FP7) to GM. We thank Paola Dalton for critical review of the
manuscript.
L Riva1,9, C Ronchini1,9, M Bodini1, F Lo-Coco2,3, S Lavorgna2,3,
T Ottone2,3, G Martinelli4, I Iacobucci4, C Tarella5, A Cignetti5,
S Volorio6, L Bernard7, A Russo7, GEM Melloni1, L Luzi6,7,
M Alcalay7,8, GI Dellino7,8 and PG Pelicci7,8
1Center for Genomic Science of IIT@SEMM, Istituto Italiano di
Tecnologia, at the IFOM-IEO Campus, Milan, Italy;
2Department of Biomedicine and Prevention, University of ‘Rome Tor
Vergata’, Rome, Italy;
3Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia,
Rome, Italy;
4Institute of Hematology ‘Sera`gnoli’, Department of Experimental,
Diagnostic and Specialty Medicine, University of Bologna,
Bologna, Italy;
5University Division of Hematology and Cell Therapy, Mauriziano
Hospital and University of Torino, Torino, Italy;
6IFOM, FIRC Institute of Molecular Oncology Foundation, Milan, Italy;
7Department of Experimental Oncology, European Institute of
Oncology, IEO, Milan, Italy and
8Dipartimento di Scienze della salute, Universita` degli Studi di
Milano, Milan, Italy
E-mail: chiara.ronchini@iit.it or piergiuseppe.pelicci@ieo.eu
9These authors contributed equally to this work.
REFERENCES
1 Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development
and acute leukemia in transgenic mice expressing PML-RAR alpha under control
of cathepsin G regulatory sequences. Blood 1997; 89: 376–387.
2 Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D et al. Cell-cycle
restriction limits DNA damage and maintains self-renewal of leukaemia stem cells.
Nature 2009; 457: 51–56.




 NK-NPM1- Complexkaryotype CBFB/ MYH11 MLL-X Trisomy 8 RUNX1/ RUNX1T1 Other  Total
a TCGAb
FLT3 9 32 9 1 3 2 1 1 5 63 x
CSMD1 3 1 0 1 0 0 0 0 1 6
WT1 3 5 5 0 1 1 0 0 2 17 x
DDR2 2 0 1 0 0 0 0 0 0 3
KRAS 2 3 2 2 0 0 1 0 1 11 x
CALR 2 0 0 0 0 0 0 0 0 2
REV3L 2 0 0 0 0 0 0 0 0 2
TCERG1L 2 0 0 0 0 0 0 0 0 2
FAM5C 1 2 0 1 0 0 0 0 1 5 x
PHF6 1 1 2 1 0 0 1 0 1 7 x
PTPN11 1 7 0 2 1 0 0 0 0 11 x
ASXL1 0 0 3 0 0 0 2 0 1 6
CEBPA 0 2 12 1 0 0 1 0 3 19 x
DNMT3A 0 29 15 3 0 0 5 0 4 56 x
EZH2 0 0 1 0 0 0 0 0 3 4 x
GATA2 0 1 6 0 0 0 0 0 0 7
GRIK2 0 2 0 0 0 1 0 0 0 3
IDH1 0 12 2 1 0 0 5 0 3 23 x
IDH2 0 5 8 1 0 0 3 0 4 21 x
KIT 0 1 0 1 3 0 0 2 1 8 x
NRAS 0 5 4 2 2 1 0 0 2 16 x
PHACTR1 0 0 0 1 0 0 0 0 2 0
PLCE1 0 0 1 0 0 0 0 1 2 4
RAD21 0 3 1 0 0 0 0 1 0 5 x
RUNX1 0 0 12 1 0 0 2 0 7 22 x
SMC1A 0 4 0 0 0 1 1 1 0 7 x
SMC3 0 3 2 1 0 0 1 1 0 8 x
STAG2 0 3 3 0 0 0 0 0 1 7 x
SUZ12 0 0 1 2 0 0 0 0 0 3
TET2 0 2 9 1 0 0 1 1 4 18 x
TP53 0 0 1 12 0 0 0 0 2 15 x
U2AF1 0 1 2 0 0 0 2 0 3 8 x
BCOR 0 0 3 0 0 0 0 0 0 3
CHD4 0 0 0 2 0 0 0 0 0 2
CTCF 0 0 2 0 0 0 0 0 0 2
DDX41 0 0 2 0 0 0 0 0 0 2
found  in ≥2 AML subgroups  
found in only one AML subgroup 
associated to a specific AML subgroup with q≥0.01 
associated to a specific AML subgroup with q≥0.05  
FAM57B 0 2 0 0 0 0 0 0 0 2
GIGYF2 0 0 0 0 0 0 0 2 0 2
GJB3 0 0 0 2 0 0 0 0 0 2
KDM3B 0 0 0 2 0 0 0 0 0 2
KRT13 0 2 0 0 0 0 0 0 0 2
PCDHA13 0 0 2 0 0 0 0 0 0 2
SCN1A 0 0 0 2 0 0 0 0 0 2
TBX15 0 2 0 0 0 0 0 0 0 2
TCEB3B 0 0 2 0 0 0 0 0 0 2
aTotal number of mutations identified for each mutated gene. bSignificantly mutated genes identified by The Cancer Genome Atlas Research network (TCGA).
Letter to the Editor
3
& 2013 Macmillan Publishers Limited Blood Cancer Journal
3 Insinga A, Cicalese A, Faretta M, Gallo B, Albano L, Ronzoni S et al. DNA damage in
stem cells activates p21, inhibits p53, and induces symmetric self-renewing
divisions. Proc Natl Acad Sci USA 2013; 110: 3931–3936.
4 Wartman LD, Larson DE, Xiang Z, Ding L, Chen K, Lin L et al. Sequencing a mouse
acute promyelocytic leukemia genome reveals genetic events relevant for disease
progression. J Clin Invest 2011; 121: 1445–1455.
5 Greif PA, Yaghmaie M, Konstandin NP, Ksienzyk B, Alimoghaddam K,
Ghavamzadeh A et al. Somatic mutations in acute promyelocytic leukemia (APL)
identiﬁed by exome sequencing. Leukemia 2011; 25: 1519–1522.
6 Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, Kulkarni S et al. Use of
whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 2011;
305: 1577–1584.
7 Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes
of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.
8 McCormack E, Bruserud O, Gjertsen BT. Review: genetic models of acute myeloid
leukaemia. Oncogene 2008; 27: 3765–3779.
9 Gaur GC, Ramadan SM, Cicconi L, Noguera NI, Luna I, Such E et al.
Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor
1 (WT1) gene in acute promyelocytic leukemia. Ann Hematol 2012; 91: 1855–1860.
10 Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W et al. Mutations in the
DDR2 kinase gene identify a novel therapeutic target in squamous cell lung
cancer. Cancer Discov 2011; 1: 78–89.
11 Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B et al.
GATA2 zinc ﬁnger 1 mutations associated with biallelic CEBPA mutations
deﬁne a unique genetic entity of acute myeloid leukemia. Blood 2012; 120:
395–403.
12 Greif PA, Eck SH, Konstandin NP, Benet-Pages A, Ksienzyk B, Dufour A et al.
Identiﬁcation of recurring tumor-speciﬁc somatic mutations in acute
myeloid leukemia by transcriptome sequencing. Leukemia 2011; 25:
821–827.
13 Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W et al.
Whole-exome sequencing identiﬁes mutations of BCOR in acute myeloid
leukemia with normal karyotype. Blood 2011; 118: 6153–6163.
14 Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y et al. Exome sequencing identiﬁes
somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic
leukemia. Nat Genet 2011; 43: 309–315.
15 Vassiliou GS, Cooper JL, Rad R, Li J, Rice S, Uren A et al. Mutant nucleophosmin
and cooperating pathways drive leukemia initiation and progression in mice. Nat
Genet 2011; 43: 470–475.
This work is licensed under a Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 Unported License. To view a copy of
this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
Supplementary Information accompanies this paper on Blood Cancer Journal website (http://www.nature.com/bcj)
Letter to the Editor
4
Blood Cancer Journal & 2013 Macmillan Publishers Limited
